Protocol Ledger

NCT06396065 · Phase III · ACTIVE NOT RECRUITING

Phase III Study of AK112 for NSCLC Patients

Interventional Phase III clinical trial protocol NCT06396065 sponsored by Summit Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-04 Enrollment: 420 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06396065
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)420 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06396065
Protocol FieldVerified Registry Value
NCT IdentifierNCT06396065
Consolidated Lead SponsorSummit Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment420 participants (ACTUAL)
Registered Start Date2023-05-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI